Literature DB >> 8932769

An in vivo analysis of cytokine production during Leishmania donovani infection in scid mice.

C R Engwerda1, S C Smelt, P M Kaye.   

Abstract

Leishmania donovani, the causative agent of visceral leishmaniasis, fails to induce NK cell activation in scid mice. In order to further our understanding of the host response to L. donovani, we analysed cytokine mRNA accumulation and TNF alpha protein synthesis in the liver of scid and BALB/c mice infected with this parasite. scid mice infected with L. donovani exhibited very little proinflammatory response, as measured by cytokine mRNA accumulation and TNF alpha protein expression, supporting the notion of a relatively "quiet" interaction between L. donovani and macrophages in these animals. In contrast, immunocompetent BALB/c mice were found to generate an early IFN gamma response, coincident with a rise in IL-2 mRNA levels and elaboration of a tissue response involving TNF alpha production by infected Kupffer cells. These results extend our understanding of the response of BALB/c and scid mice to L. donovani infection and highlight the value of cytokine analysis at both the tissue and cellular levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932769     DOI: 10.1006/expr.1996.0105

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  19 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice.

Authors:  P Escobar; V Yardley; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Chronic Leishmania donovani infection promotes bystander CD8+-T-cell expansion and heterologous immunity.

Authors:  Rosalind Polley; Stephanie L Sanos; Sara Prickett; Ashraful Haque; Paul M Kaye
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy.

Authors:  Henry W Murray; Christina M Lu; Smita Mauze; Sherry Freeman; Andre L Moreira; Gilla Kaplan; Robert L Coffman
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

5.  Enhanced hematopoietic activity accompanies parasite expansion in the spleen and bone marrow of mice infected with Leishmania donovani.

Authors:  S E Cotterell; C R Engwerda; P M Kaye
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

6.  Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection.

Authors:  Asher Maroof; Paul M Kaye
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

7.  A role for tumor necrosis factor-alpha in remodeling the splenic marginal zone during Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Sara E J Cotterell; Tracey L Mynott; Asiya Tschannerl; Patricia M A Gorak-Stolinska; Paul M Kaye
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 8.  Cytokines and their STATs in cutaneous and visceral leishmaniasis.

Authors:  Hannah E Cummings; Rashmi Tuladhar; Abhay R Satoskar
Journal:  J Biomed Biotechnol       Date:  2010-03-15

9.  Innate killing of Leishmania donovani by macrophages of the splenic marginal zone requires IRF-7.

Authors:  Rebecca Phillips; Mattias Svensson; Naveed Aziz; Asher Maroof; Najmeeyah Brown; Lynette Beattie; Nathalie Signoret; Paul M Kaye
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

10.  A Leishmania infantum cytosolic tryparedoxin activates B cells to secrete interleukin-10 and specific immunoglobulin.

Authors:  Sofia Menezes Cabral; Ricardo Leal Silvestre; Nuno Moreira Santarém; Joana Costa Tavares; Ana Franco Silva; Anabela Cordeiro-da-Silva
Journal:  Immunology       Date:  2007-11-17       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.